Ask AI
ProCE Banner Activity

Considerations in Selecting Therapy for Previously Treated Chronic Lymphocytic Leukemia

Slideset Download

Download this slideset from a live symposium at ASH 2021 for expert perspectives on best practices in treating patients with relapsed/refractory CLL.

Released: December 09, 2021

Share

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Genentech, a member of the Roche Group

Janssen Biotech Pharmacyclics Abbvie

Faculty Disclosure

Primary Author

Brian Hill, MD, PhD

Director of the Lymphoid Malignancies Program
Associate Professor, Cleveland Clinic Lerner College of Medicine
Staff Physician
Department of Hematology & Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Brian Hill, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Genentech, Pharmacyclics; researcher: AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Genentech, Nurix, Pharmacylics.

Additional Information

Program Medium

This program has been made available online.